Literature DB >> 18839463

Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.

Carsten Stephan1, Anna-Maria Kahrs, Silke Klotzek, Janett Reiche, Christian Müller, Michael Lein, Serdar Deger, Kurt Miller, Klaus Jung.   

Abstract

BACKGROUND: The metrological traceability of prostate-specific antigen (PSA) assay calibration to WHO standards is desirable to potentially improve the comparability between PSA assays. A method comparison was performed between the traditionally standardized Beckman Coulter Hybritech Access PSA and free PSA (fPSA) assays and a new alternate calibration of assays aligned to the WHO standards 96/670 and 96/668, respectively.
METHODS: Sera from 641 men with and without prostate cancer, various control materials and mixtures of different proportions of the WHO standards were measured with both assay calibrations.
RESULTS: Excellent comparability between the corresponding assay calibrations was observed, with correlation coefficients of at least 0.996. The Passing-Bablok slopes were 0.747 for total PSA (tPSA), 0.776 for fPSA and 1.02 for the percentage ratio of fPSA to tPSA (%fPSA), while the corresponding percentages of the new WHO-aligned assay results related to the traditional assays were 76.2%, 77% and 102.2%. Receiver operating characteristics revealed no differences between the two PSA assay calibrations.
CONCLUSIONS: The WHO calibration yields results approximately 25% lower for tPSA and fPSA values when compared with the conventional Hybritech calibration. Using the WHO-aligned PSA assay, a tPSA cut-off of 3 microg/L should be considered in clinical practice, while %fPSA cut-offs could be retained.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839463     DOI: 10.1515/cclm.2008.129

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Prostate cancer: WHO standardization of PSA tests: clinical consequences.

Authors:  Carsten Stephan
Journal:  Nat Rev Urol       Date:  2009-06       Impact factor: 14.432

2.  Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

Authors:  Danni L Meany; Lori J Sokoll; Daniel W Chan
Journal:  Expert Opin Med Diagn       Date:  2009-11-01

Review 3.  Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.

Authors:  George Botchorishvili; Mika P Matikainen; Hans Lilja
Journal:  Curr Opin Urol       Date:  2009-05       Impact factor: 2.309

Review 4.  A review of standards and statistics used to describe blood glucose monitor performance.

Authors:  Jan S Krouwer; George S Cembrowski
Journal:  J Diabetes Sci Technol       Date:  2010-01-01

Review 5.  Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

Authors:  Zhongwei Zhao; Carsten Stephan; Sabine Weickmann; Monika Jung; Glen Kristiansen; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.